279 related articles for article (PubMed ID: 35569438)
1. Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study.
Machingura A; Taye M; Musoro J; Ringash J; Pe M; Coens C; Martinelli F; Tu D; Basch E; Brandberg Y; Grønvold M; Eggermont A; Cardoso F; Van Meerbeeck J; van der Graaf WTA; Taphoorn M; Reijneveld JC; Soffietti R; Sloan J; Velikova G; Flechtner H; Bottomley A;
Eur J Cancer; 2022 Jul; 170():1-9. PubMed ID: 35569438
[TBL] [Abstract][Full Text] [Related]
2. Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.
Martinelli F; Quinten C; Maringwa JT; Coens C; Vercauteren J; Cleeland CS; Flechtner H; Gotay C; Greimel E; King M; Mendoza T; Osoba D; Reeve BB; Ringash J; Koch JS; Shi Q; Taphoorn MJ; Weis J; Bottomley A;
Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):587-99. PubMed ID: 21958103
[TBL] [Abstract][Full Text] [Related]
3. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
Aaronson NK; Ahmedzai S; Bergman B; Bullinger M; Cull A; Duez NJ; Filiberti A; Flechtner H; Fleishman SB; de Haes JC
J Natl Cancer Inst; 1993 Mar; 85(5):365-76. PubMed ID: 8433390
[TBL] [Abstract][Full Text] [Related]
4. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
5. International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
Oerlemans S; Efficace F; Kyriakou C; Freitas AC; Shamieh O; Creutzberg CL; Lehmann J; Petranovic D; Nagele E; Bredart A; Dong D; Scholz CW; Caocci G; Molica S; Griskevicius L; Xochelli A; Kieffer JM; Agelink van Rentergem JA; Alrjoub W; Mueller A; Gomes Da Silva M; Alves da Costa F; Malak S; Cocks K; van de Poll-Franse LV;
Cancer; 2023 Sep; 129(17):2727-2740. PubMed ID: 37204189
[TBL] [Abstract][Full Text] [Related]
6. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
[TBL] [Abstract][Full Text] [Related]
7. Validation and comparison of the health-related quality-of-life instruments EORTC QLQ-C30 and SF-36 in assessment of patients with chronic nonmalignant pain.
Fredheim OM; Borchgrevink PC; Saltnes T; Kaasa S
J Pain Symptom Manage; 2007 Dec; 34(6):657-65. PubMed ID: 17618079
[TBL] [Abstract][Full Text] [Related]
8. General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition.
Arraras JI; Nolte S; Liegl G; Rose M; Manterola A; Illarramendi JJ; Zarandona U; Rico M; Teiejria L; Asin G; Hernandez I; Barrado M; Vera R; Efficace F; Giesinger JM;
Health Qual Life Outcomes; 2021 Aug; 19(1):208. PubMed ID: 34461909
[TBL] [Abstract][Full Text] [Related]
9. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.
Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT
Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722
[TBL] [Abstract][Full Text] [Related]
10. The assessment of health-related quality of life and related factors in Chinese elderly patients undergoing chemotherapy for advanced cancer: a cross-sectional study.
Li Q; Lin Y; Qiu Y; Gao B; Xu Y
Eur J Oncol Nurs; 2014 Aug; 18(4):425-35. PubMed ID: 24721179
[TBL] [Abstract][Full Text] [Related]
11. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.
Maringwa JT; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Vercauteren J; Cleeland CS; Flechtner H; Gotay C; Greimel E; Taphoorn MJ; Reeve BB; Koch JS; Weis J; Smit EF; van Meerbeeck JP; Bottomley A;
Support Care Cancer; 2011 Nov; 19(11):1753-60. PubMed ID: 20886240
[TBL] [Abstract][Full Text] [Related]
12. The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative.
Zikos E; Coens C; Quinten C; Ediebah DE; Martinelli F; Ghislain I; King MT; Gotay C; Ringash J; Velikova G; Reeve BB; Greimel E; Cleeland CS; Flechtner H; Taphoorn MJ; Weis J; Schmucker-von Koch J; Sprangers MA; Bottomley A;
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26714759
[TBL] [Abstract][Full Text] [Related]
13. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients.
Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W
Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
15. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
Coomans MB; Dirven L; Aaronson NK; Baumert BG; Van Den Bent M; Bottomley A; Brandes AA; Chinot O; Coens C; Gorlia T; Herrlinger U; Keime-Guibert F; Malmström A; Martinelli F; Stupp R; Talacchi A; Weller M; Wick W; Reijneveld JC; Taphoorn MJB
Neuro Oncol; 2019 Nov; 21(11):1447-1457. PubMed ID: 31682733
[TBL] [Abstract][Full Text] [Related]
16. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain.
Giesinger JM; Kuijpers W; Young T; Tomaszewski KA; Friend E; Zabernigg A; Holzner B; Aaronson NK
Health Qual Life Outcomes; 2016 Jun; 14():87. PubMed ID: 27267486
[TBL] [Abstract][Full Text] [Related]
17. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study.
de Ligt KM; Aaronson NK; Liegl G; Nolte S;
Qual Life Res; 2023 Sep; 32(9):2477-2487. PubMed ID: 37031427
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in glioma patients in China.
Cheng JX; Liu BL; Zhang X; Lin W; Zhang YQ; Liu WP; Zhang JN; Lin H; Wang R; Yin H
BMC Cancer; 2010 Jun; 10():305. PubMed ID: 20565883
[TBL] [Abstract][Full Text] [Related]
19. Test-Retest Reliability of an Interactive Voice Response (IVR) Version of the EORTC QLQ-C30.
Lundy JJ; Coons SJ; Aaronson NK
Patient; 2015 Apr; 8(2):165-70. PubMed ID: 24958466
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
